SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR)...
Hence then, the article about dizal to present emerging data on zegfrovy in non small cell lung cancer at wclc 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 )
Also on site :
- Fans Rally Behind ‘Vampire Diaries’ Star Steven R. McQueen, 38, After Years Away
- Jamie Lee Curtis Pays Heartfelt Tribute to Oscar-Nominated Mother Janet Leigh on Anniversary of Her Death: ‘Love and Misses to My Mother’
- Tom Morello Says He Didn’t Vote for Kamala Harris in 2024